CheckMate227 found that NSCLC patients who received nivolumab plus ipilimumab therapy as first-line therapy had better overall survival (OS) than those who received chemotherapy, and this outcome was independent of PD-L1 expression (10). This evidence concerns the gene CD274 and non-small cell lung carcinoma.